Iguratimod
( DrugBank: Iguratimod / KEGG DRUG: Iguratimod )
6 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 20 |
| 49 | Systemic lupus erythematosus | 1 |
| 51 | Scleroderma | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 7 |
| 271 | Ankylosing spondylitis | 2 |
| 300 | IgG4-related disease | 2 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,543 / Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. Systemic lupus erythematosus
Clinical trials : 1,227 / Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
51. Scleroderma
Clinical trials : 639 / Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
53. Sjogren syndrome
Clinical trials : 368 / Drugs : 277 - (DrugBank : 94) / Drug target genes : 62 - Drug target pathways : 186
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
271. Ankylosing spondylitis
Clinical trials : 603 / Drugs : 302 - (DrugBank : 69) / Drug target genes : 40 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
300. IgG4-related disease
Clinical trials : 57 / Drugs : 52 - (DrugBank : 29) / Drug target genes : 20 - Drug target pathways : 147
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|